• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《Cure SMA 会员调查》:脊髓性肌萎缩症个体关键人口统计学和临床特征要点。

The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.

机构信息

Cure SMA, Elk Grove Village, IL, USA.

Biogen, Cambridge, MA, USA.

出版信息

J Neuromuscul Dis. 2021;8(1):109-123. doi: 10.3233/JND-200563.

DOI:10.3233/JND-200563
PMID:33104036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7902958/
Abstract

BACKGROUND

Cure SMA maintains the largest patient-reported database for people affected with spinal muscular atrophy (SMA). In 2017, Cure SMA initiated annual surveys with their membership to collect demographic and disease characteristics, healthcare, and burden of disease information from patients and caregivers.

OBJECTIVE

To summarize results from two large-scale Cure SMA surveys in 2017 and 2018.

METHODS

Cure SMA database members were invited to complete surveys; these were completed by caregivers for living or deceased individuals with SMA and/or affected adults.

RESULTS

In 2017, 726 surveys were completed for 695 individuals with SMA; in 2018, 796 surveys were completed for 760 individuals with SMA. Data from both survey years are available for 313 affected individuals. Age at symptom onset, distribution of SMN2 gene copy number, and representation of each SMA type in the surveys were consistent with that expected in the SMA population. In the 2018 survey, the average age at diagnosis was 5.2 months for SMA type I and the reported mean age at death for this subgroup was 27.8 months. Between survey years, there was consistency in responses for factors that should not change within individuals over time (e.g., reported age at diagnosis).

CONCLUSIONS

Results from the Cure SMA surveys advance the understanding of SMA and facilitate advocacy efforts and healthcare services planning. Longitudinal surveys are important for evaluating the impact of effective treatments on changing phenotypes, and burden of disease and care in individuals with SMA.

摘要

背景

Cure SMA 维护着最大的脊髓性肌萎缩症(SMA)患者报告数据库。2017 年,Cure SMA 开始对其会员进行年度调查,以从患者和护理人员那里收集人口统计学和疾病特征、医疗保健以及疾病负担信息。

目的

总结 2017 年和 2018 年两次 Cure SMA 大型调查的结果。

方法

邀请 Cure SMA 数据库成员完成调查;这些调查由 SMA 患者和/或受影响的成年人的护理人员完成。

结果

2017 年,有 726 名 SMA 患者完成了 726 份调查;2018 年,有 760 名 SMA 患者完成了 796 份调查。来自这两年调查的数据可用于 313 名受影响的个体。发病年龄、SMN2 基因拷贝数分布以及各型 SMA 在调查中的表现与 SMA 人群中的预期一致。在 2018 年的调查中,SMA 型 I 的平均诊断年龄为 5.2 个月,该亚组报告的平均死亡年龄为 27.8 个月。在调查年份之间,对于不应随时间在个体中变化的因素(例如,报告的诊断年龄)的反应保持一致。

结论

Cure SMA 调查的结果增进了对 SMA 的认识,并有助于倡导工作和医疗保健服务计划。纵向调查对于评估有效治疗对改变表型以及 SMA 患者的疾病负担和护理的影响非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c4/7902958/66c50f4d2c1b/jnd-8-jnd200563-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c4/7902958/1b7512fcb190/jnd-8-jnd200563-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c4/7902958/66c50f4d2c1b/jnd-8-jnd200563-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c4/7902958/1b7512fcb190/jnd-8-jnd200563-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c4/7902958/66c50f4d2c1b/jnd-8-jnd200563-g002.jpg

相似文献

1
The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.《Cure SMA 会员调查》:脊髓性肌萎缩症个体关键人口统计学和临床特征要点。
J Neuromuscul Dis. 2021;8(1):109-123. doi: 10.3233/JND-200563.
2
An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members.SMA 患者数据库概述:SMA 患者主要人口统计学和临床特征要点。
J Neuromuscul Dis. 2018;5(2):167-176. doi: 10.3233/JND-170292.
3
Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.加拿大脊髓性肌萎缩症(SMA)患者和照护者的负担。
J Neuromuscul Dis. 2021;8(4):553-568. doi: 10.3233/JND-200610.
4
Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.评估脊髓性肌萎缩症的获益-风险决策:首次评估 SMA 患者群体风险承受能力的研究。
Clin Ther. 2019 May;41(5):943-960.e4. doi: 10.1016/j.clinthera.2019.03.012. Epub 2019 May 3.
5
Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey.脊髓性肌萎缩症患者的生活质量数据:来自 Cure SMA 社区更新调查的基线数据集。
Orphanet J Rare Dis. 2020 Aug 24;15(1):217. doi: 10.1186/s13023-020-01498-2.
6
"I have SMA, SMA doesn't have me": a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA.“SMA 无法定义我”:一项青少年和青年 SMA 患者挑战、成功和生活质量的定性快照研究。
Orphanet J Rare Dis. 2021 Feb 22;16(1):96. doi: 10.1186/s13023-021-01701-y.
7
Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy.观察 3 型脊髓性肌萎缩症的自然病程:来自波兰脊髓性肌萎缩症登记处的数据。
Orphanet J Rare Dis. 2021 Mar 24;16(1):150. doi: 10.1186/s13023-021-01771-y.
8
Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.西班牙脊髓性肌萎缩症(SMA)患者的社会/经济成本和与健康相关的生活质量。
Orphanet J Rare Dis. 2017 Aug 18;12(1):141. doi: 10.1186/s13023-017-0695-0.
9
Survey of patients with spinal muscular atrophy on the island of Shikoku, Japan.日本四国岛脊髓性肌萎缩症患者调查。
Brain Dev. 2020 Sep;42(8):594-602. doi: 10.1016/j.braindev.2020.05.004. Epub 2020 Jun 3.
10
Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.脊髓性肌萎缩症治疗中依洛硫酸酯酶β的早期经验:来自对患者和照护者的大型调查结果。
Muscle Nerve. 2021 Mar;63(3):311-319. doi: 10.1002/mus.27116. Epub 2020 Dec 19.

引用本文的文献

1
SMA Community Priorities for Future Drug Therapies: Cross-Sectional Survey Findings Representing 410 Adults with SMA.脊髓性肌萎缩症患者群体对未来药物治疗的优先需求:涵盖410名脊髓性肌萎缩症成年患者的横断面调查结果
Neurol Ther. 2025 Jun;14(3):1083-1092. doi: 10.1007/s40120-025-00753-7. Epub 2025 May 3.
2
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study.阿哌特格罗单抗治疗脊髓性肌萎缩症患者的长期疗效、安全性及患者报告结局:36个月TOPAZ研究结果
Front Neurol. 2024 Jul 22;15:1419791. doi: 10.3389/fneur.2024.1419791. eCollection 2024.
3

本文引用的文献

1
Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.Onasemnogene Abeparvovec-xioi:脊髓性肌萎缩症的基因治疗。
Ann Pharmacother. 2020 Oct;54(10):1001-1009. doi: 10.1177/1060028020914274. Epub 2020 Mar 23.
2
Drug treatment for spinal muscular atrophy types II and III.脊髓性肌萎缩症II型和III型的药物治疗。
Cochrane Database Syst Rev. 2020 Jan 6;1(1):CD006282. doi: 10.1002/14651858.CD006282.pub5.
3
Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next.
The impact of three gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review.
三个基因拷贝对脊髓性肌萎缩症患者临床特征及疾病修饰治疗效果的影响:一项系统文献综述
Front Neurol. 2024 Feb 29;15:1308296. doi: 10.3389/fneur.2024.1308296. eCollection 2024.
4
Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.脊髓性肌萎缩症自然史的系统文献回顾:运动功能、脊柱侧凸和挛缩。
Neurology. 2023 Nov 21;101(21):e2103-e2113. doi: 10.1212/WNL.0000000000207878. Epub 2023 Oct 9.
5
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey.患者和照护者结局在onasemnogene abeparvovec 治疗后:来自 Cure SMA 2021 会员调查的发现。
Adv Ther. 2023 Dec;40(12):5315-5337. doi: 10.1007/s12325-023-02685-w. Epub 2023 Sep 30.
6
Evaluating the Use of PROMs in Paediatric Orthopaedic Registries.评估患者报告结局量表在儿科骨科登记处的应用。
Children (Basel). 2023 Sep 14;10(9):1552. doi: 10.3390/children10091552.
7
Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany.SMA 医疗护理的改进领域:来自德国全国患者登记处的证据。
Orphanet J Rare Dis. 2023 Feb 21;18(1):32. doi: 10.1186/s13023-023-02639-z.
8
Knowledge of genetic test results among caregivers and individuals with spinal muscular atrophy.照顾者和脊髓性肌萎缩症患者对基因检测结果的了解。
PLoS One. 2022 Nov 8;17(11):e0276756. doi: 10.1371/journal.pone.0276756. eCollection 2022.
9
Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy.调查对脊髓性肌萎缩症产前诊断和胎儿治疗的态度。
Prenat Diagn. 2022 Oct;42(11):1409-1419. doi: 10.1002/pd.6228. Epub 2022 Sep 3.
脊髓性肌萎缩症研究 25 年:从表型到基因型再到治疗,以及接下来的发展。
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:231-261. doi: 10.1146/annurev-genom-102319-103602. Epub 2020 Jan 31.
4
New treatments in spinal muscular atrophy: an overview of currently available data.脊髓性肌萎缩症的新治疗方法:现有数据概述。
Expert Opin Pharmacother. 2020 Feb;21(3):307-315. doi: 10.1080/14656566.2019.1704732.
5
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands.第244届ENMC国际研讨会:脊髓性肌萎缩症的新生儿筛查,2019年5月10日至12日,荷兰霍夫多普
Neuromuscul Disord. 2020 Jan;30(1):93-103. doi: 10.1016/j.nmd.2019.11.002. Epub 2019 Nov 9.
6
Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort.脊髓性肌萎缩症(SMA)亚型在兄弟姐妹中的一致性:来自 Cure SMA 队列的研究结果。
J Neuromuscul Dis. 2020;7(1):33-40. doi: 10.3233/JND-190399.
7
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.在脊髓性肌萎缩症的前症状期对婴儿期开始用 nusinersen:2 期 NURTURE 研究的中期疗效和安全性结果。
Neuromuscul Disord. 2019 Nov;29(11):842-856. doi: 10.1016/j.nmd.2019.09.007. Epub 2019 Sep 12.
8
Long-term progression in type II spinal muscular atrophy: A retrospective observational study.《Ⅱ型脊髓性肌萎缩症的长期进展:一项回顾性观察研究》
Neurology. 2019 Sep 24;93(13):e1241-e1247. doi: 10.1212/WNL.0000000000008166. Epub 2019 Aug 26.
9
Onasemnogene Abeparvovec: First Global Approval.Onasemnogene Abeparvovec:全球首次获批。
Drugs. 2019 Jul;79(11):1255-1262. doi: 10.1007/s40265-019-01162-5.
10
Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.评估脊髓性肌萎缩症的获益-风险决策:首次评估 SMA 患者群体风险承受能力的研究。
Clin Ther. 2019 May;41(5):943-960.e4. doi: 10.1016/j.clinthera.2019.03.012. Epub 2019 May 3.